

Giandomenico Roviello

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/241403/giandomenico-roviello-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

192
papers

2,190
citations

24
h-index

40
g-index

220
ext. papers

2,915
ext. citations

4.2
avg, IF

5.34
L-index

#	Paper	IF	Citations
192	Current status and future perspectives in HER2 positive advanced gastric cancer.. <i>Clinical and Translational Oncology</i> , 2022 , 1	3.6	3
191	Gastric and colonic metastasis from NSCLC: A very unusual case report.. <i>Medicine (United States)</i> , 2022 , 101, e28249	1.8	0
190	NTRK Fusions Detection in Paediatric Sarcomas to Expand the Morphological Spectrum and Clinical Relevance of Selected Entities.. <i>Pathology and Oncology Research</i> , 2022 , 28, 1610237	2.6	0
189	Therapeutic management of a symptomatic Kaposi's sarcoma patient with renal failure undergoing haemodialysis: A case report.. <i>Dermatology Reports</i> , 2022 , 14, 9113	0.9	0
188	The impact of age, performance status and comorbidities on nab-paclitaxel plus gemcitabine effectiveness in patients with metastatic pancreatic cancer.. <i>Scientific Reports</i> , 2022 , 12, 8244	4.9	0
187	Genetic parkinsonisms and cancer: a systematic review and meta-analysis. <i>Reviews in the Neurosciences</i> , 2021 , 32, 159-167	4.7	3
186	Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21). <i>Expert Review of Anticancer Therapy</i> , 2021 , 1-7	3.5	2
185	Interdisciplinary insights into the link between gut microbiome and gastric carcinogenesis-what is currently known?. <i>Gastric Cancer</i> , 2021 , 1	7.6	4
184	NTRK Gene Fusion Detection in Atypical Spitz Tumors. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	2
183	p53 Antibodies as a Diagnostic Marker for Cancer: A Meta-Analysis. <i>Molecules</i> , 2021 , 26,	4.8	2
182	Is there a preferred first-line therapy for metastatic renal cell carcinoma? A network meta-analysis. <i>Therapeutic Advances in Urology</i> , 2021 , 13, 17562872211053189	3.2	2
181	Darolutamide in hormone-sensitive and castration-resistant prostate cancer. <i>Expert Review of Clinical Pharmacology</i> , 2021 , 14, 535-544	3.8	0
180	Human epidermal growth factor receptor 2 (HER2) in advanced gastric cancer: where do we stand?. <i>Gastric Cancer</i> , 2021 , 24, 765-779	7.6	4
179	Second line of treatment for HER2-positive gastric cancer: an evolving issue. <i>Reports of Practical Oncology and Radiotherapy</i> , 2021 , 26, 316-317	1.5	1
178	Association between Low-Grade Chemotherapy-Induced Peripheral Neuropathy (CINP) and Survival in Patients with Metastatic Adenocarcinoma of the Pancreas. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	1
177	Maintenance in gastric cancer: New life for an old issue?. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 160, 103307	7	1
176	Beyond Conventional: The New Horizon of Targeted Therapy for the Treatment of Advanced Non Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021 , 11, 632256	5.3	4

175	EGFR mutation analysis on circulating free DNA in NSCLC: a single-center experience. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021 , 147, 2301-2307	4.9	
174	Immune checkpoint inhibitors and chemotherapy in first-line NSCLC: a meta-analysis. <i>Immunotherapy</i> , 2021 , 13, 621-631	3.8	16
173	Endocrine-related adverse events in a large series of cancer patients treated with anti-PD1 therapy. <i>Endocrine</i> , 2021 , 74, 172-179	4	2
172	Impact of Previous Nephrectomy on Clinical Outcome of Metastatic Renal Carcinoma Treated With Immune-Oncology: A Real-World Study on Behalf of Meet-URO Group (MeetUro-7b). <i>Frontiers in Oncology</i> , 2021 , 11, 682449	5.3	3
171	Pharmacogenetics in diffuse large B-cell lymphoma treated with R-CHOP: Still an unmet challenge. <i>Pharmacology & Therapeutics</i> , 2021 , 229, 107924	13.9	0
170	Comparing immunotherapies to other frequently used treatments of gastric cancer. <i>Expert Review of Clinical Pharmacology</i> , 2021 , 14, 1221-1232	3.8	0
169	Lenvatinib: established and promising drug for the treatment of advanced hepatocellular carcinoma. <i>Expert Review of Clinical Pharmacology</i> , 2021 , 14, 1353-1365	3.8	0
168	ALERTASTE: improving food pleasure and intake of oncology patients receiving chemotherapy. <i>Future Oncology</i> , 2021 , 17, 2573-2579	3.6	1
167	Treating De Novo Metastatic Castration-Sensitive Prostate Cancer With Visceral Metastases: An Evolving Issue. <i>Clinical Genitourinary Cancer</i> , 2021 , 19, 83-86	3.3	1
166	Advances in anti-BRAF therapies for lung cancer. <i>Investigational New Drugs</i> , 2021 , 39, 879-890	4.3	8
165	Cabozantinib (Cabo) beyond progression improves survival in advanced renal cell carcinoma patients: The CABEYOND study (Meet-Uro 21).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 320-320	2.2	0
164	A multicenter, retrospective study on impact of immunotherapy in urothelial carcinoma with bone metastases (Meet-Uro01 Study).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 401-401	2.2	1
163	Tumor Type Agnostic Therapy Carrying BRAF Mutation: Case Reports and Review of Literature. <i>Pharmaceuticals</i> , 2021 , 14,	5.2	2
162	The effects of hepatitis B virus infection on natural and IVF pregnancy: A meta-analysis study. <i>Journal of Viral Hepatitis</i> , 2021 , 28, 1234-1245	3.4	1
161	Gut Microbiota Modulation in the Context of Immune-Related Aspects of spp. and spp. in Gastrointestinal Cancers. <i>Nutrients</i> , 2021 , 13,	6.7	8
160	Eosinophil Count as Predictive Biomarker of Immune-Related Adverse Events (irAEs) in Immune Checkpoint Inhibitors (ICIs) Therapies in Oncological Patients. <i>Immuno</i> , 2021 , 1, 253-263		3
159	Clinical outcome of renal cancer patients who early interrupted immunotherapy due to serious immune-related adverse events. Meet-Uro 13 trial on behalf of the MeetUro investigators. <i>Journal of Translational Medicine</i> , 2021 , 19, 328	8.5	0
158	Immune Checkpoint Inhibitors in Urothelial Bladder Cancer: State of the Art and Future Perspectives. <i>Cancers</i> , 2021 , 13,	6.6	8

157	The gut microbiome and efficacy of cancer immunotherapy. <i>Pharmacology & Therapeutics</i> , 2021 , 231, 107973	13.9	7
156	Lu-PSMA Radioligand Therapy Is Favorable as Third-Line Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. <i>Biomedicines</i> , 2021 , 9,	4.8	4
155	Gut Microbiome Modulation and Faecal Microbiota Transplantation Following Allogenic Hematopoietic Stem Cell Transplantation. <i>Cancers</i> , 2021 , 13,	6.6	1
154	Rechallenge of immune checkpoint inhibitors: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 165, 103434	7	6
153	Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism?. <i>Therapeutic Advances in Urology</i> , 2021 , 13, 17562872211029784	3.2	1
152	FOLFOX vs FOLFIRI as Second-line of Therapy After Progression to Gemcitabine/Nab-paclitaxel in Patients with Metastatic Pancreatic Cancer. <i>Cancer Management and Research</i> , 2020 , 12, 10271-10278	3.6	3
151	Methylene Blue-Current Knowledge, Fluorescent Properties, and Its Future Use. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	17
150	TAS-102 in gastric cancer: Development and perspectives of a new biochemically modulated fluroropyrimidine drug combination. <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 152, 102987	7	3
149	TRK fusion positive cancers: From first clinical data of a TRK inhibitor to future directions. <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 152, 103011	7	8
148	MSI and EBV Positive Gastric Cancer Subgroups and Their Link With Novel Immunotherapy. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	30
147	Cabozantinib as a second-line treatment option in hepatocellular carcinoma. <i>Expert Review of Clinical Pharmacology</i> , 2020 , 13, 623-629	3.8	4
146	Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. <i>Translational Oncology</i> , 2020 , 13, 100795	4.9	14
145	In reply to Egger et al.: Lack of benefit from adjuvant postoperative radiotherapy and issues raised about upfront management of high- and very-high-risk prostate cancer patients. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2020 , 64, 595-596	1.7	
144	Evaluation of targetable biomarkers for chimeric antigen receptor T-cell (CAR-T) in the treatment of pancreatic cancer: a systematic review and meta-analysis of preclinical studies. <i>International Reviews of Immunology</i> , 2020 , 39, 223-232	4.6	1
143	Association between neutropenia and response to ramucirumab and paclitaxel in patients with metastatic gastric cancer. <i>Anti-Cancer Drugs</i> , 2020 , 31, 632-636	2.4	2
142	An overview of the clinical use of cabozantinib in the treatment of advanced non-clear-cell renal cell carcinoma (NCCRCC). <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 149, 102921	7	3
141	Immune Checkpoint Inhibitors in Pre-Treated Gastric Cancer Patients: Results from a Literature-Based Meta-Analysis. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	3
140	Perioperative chemotherapy for gastric cancer in FLOT4. <i>Lancet, The</i> , 2020 , 395, e3	40	3

139	Radiotherapy after prostatectomy in high-risk prostate cancer. <i>Clinical and Translational Oncology</i> , 2020 , 22, 2139-2140	3.6	1
138	Baseline and early change of systemic inflammation index (bSII and SII) as prognostic factors in metastatic renal cell carcinoma (mRCC) patients treated with Nivolumab: Final results of the Meet-URO 15 (I-BIO-REC) study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 5072-5072	2.2	1
137	Clinical outcomes of metastatic renal carcinoma following disease progression to programmed death (PD)-1 or PD-L1 inhibitors (I-O): A Meet-URO group real-world study (Meet-Uro 7).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 691-691	2.2	1
136	Clinical Outcomes and Safety of Patients Treated with NAb-Paclitaxel Plus Gemcitabine in Metastatic Pancreatic Cancer: The NAPA Study. <i>Current Cancer Drug Targets</i> , 2020 , 20, 887-895	2.8	4
135	Prognostic role of T3/T4 ratio in metastatic renal cell carcinoma (mRCC): Preliminary results of the threeFOUR multicenter study (Meet-Uro 14).. <i>Journal of Clinical Oncology</i> , 2020 , 38, e17093-e17093	2.2	
134	Impact of previous nephrectomy on clinical outcome of metastatic renal carcinoma treated with immune-oncology (I-O):A real-world study on behalf of Meet-URO group (MeetUro-7b).. <i>Journal of Clinical Oncology</i> , 2020 , 38, e17088-e17088	2.2	
133	Corticosteroid switch after progression on abiraterone acetate plus prednisone. <i>International Journal of Clinical Oncology</i> , 2020 , 25, 240-246	4.2	7
132	The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer. <i>Liver International</i> , 2020 , 40, 704-711	7.9	25
131	Defining the Ideal Patient with Hepatocellular Carcinoma for Second-Line Treatment. <i>Journal of Oncology</i> , 2020 , 2020, 8024124	4.5	1
130	Expression patterns and clinical significance of the potential cancer stem cell markers OCT4 and NANOG in colorectal cancer patients. <i>Molecular and Cellular Oncology</i> , 2020 , 7, 1788366	1.2	10
129	Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies. <i>Cancers</i> , 2020 , 12,	6.6	18
128	Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer. <i>Scientific Reports</i> , 2020 , 10, 19281	4.9	4
127	Focus on Biochemical and Clinical Predictors of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma: Where Do We Stand?. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	11
126	How the CARD trial has changed the cards on the table for metastatic castration resistant prostate cancer. <i>Reports of Practical Oncology and Radiotherapy</i> , 2020 , 25, 701-702	1.5	
125	Overview of the clinical use of erdafitinib as a treatment option for the metastatic urothelial carcinoma: where do we stand. <i>Expert Review of Clinical Pharmacology</i> , 2020 , 13, 1139-1146	3.8	6
124	Electronic nicotine delivery systems (ENDS): not still ready to put on END. <i>Journal of Thoracic Disease</i> , 2020 , 12, 3857-3865	2.6	4
123	Role of novel hormonal therapies in the management of non-metastatic castration-resistant prostate cancer: a literature-based meta-analysis of randomized trials. <i>Clinical and Translational Oncology</i> , 2020 , 22, 1033-1039	3.6	10
122	Role of ATP-binding cassette transporters in cancer initiation and progression. <i>Seminars in Cancer Biology</i> , 2020 , 60, 72-95	12.7	24

121	Immunotherapy-based combinations versus standard first-line and hypothyroidism risk. <i>Clinical and Translational Oncology</i> , 2020 , 22, 1664-1665	3.6	1
120	Tumor-Agnostic Treatment for Cancer: When How is Better than Where. <i>Clinical Drug Investigation</i> , 2020 , 40, 519-527	3.2	16
119	The influence of prior ramucirumab treatment on the clinical activity of FOLFIRI as third-line therapy in patients with metastatic gastric Cancer. <i>Investigational New Drugs</i> , 2019 , 37, 524-530	4.3	2
118	Abiraterone plus prednisone or enzalutamide in patients with metastatic castration-resistant prostate cancer: is a question of quality?. <i>AME Medical Journal</i> , 2019 , 4, 24-24	1	
117	Nanoparticle albumin-bound paclitaxel: a big nano for the treatment of gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2019 , 84, 669-677	3.5	9
116	Efficacy of extended aromatase inhibitors for hormone-receptor-positive breast cancer: A literature-based meta-analysis of randomized trials. <i>Breast</i> , 2019 , 46, 19-24	3.6	7
115	To surrogate or not surrogate: an ancient dilemma without a happy ending. <i>Journal of Hospital Management and Health Policy</i> , 2019 , 3, 6-6	0.5	0
114	Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma. <i>Molecular Biology Reports</i> , 2019 , 46, 2713-2720	2.8	11
113	Ramucirumab as a second line therapy for advanced HCC: a significant achievement or a wasted opportunity for personalised therapy?. <i>Investigational New Drugs</i> , 2019 , 37, 1274-1288	4.3	7
112	Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer. <i>Cells</i> , 2019 , 8,	7.9	70
111	New-Generation Hormone Therapies in Nonmetastatic Castration-Resistant Prostate Cancer: Why, Who, When. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, e534-e535	3.3	
110	Tumour infiltrating lymphocytes and immune-related genes as predictors of outcome in pancreatic adenocarcinoma. <i>PLoS ONE</i> , 2019 , 14, e0219566	3.7	11
109	Results from a meta-analysis of immune checkpoint inhibitors in first-line renal cancer patients: does PD-L1 matter?. <i>Therapeutic Advances in Medical Oncology</i> , 2019 , 11, 1758835919861905	5.4	21
108	Is there still a place for vinorelbine in advanced metastatic castration resistant prostate cancer?. <i>Medicine (United States)</i> , 2019 , 98, e16249	1.8	
107	Anti-PD-1 versus anti-PD-L1 therapy in patients with pretreated advanced non-small-cell lung cancer: a meta-analysis. <i>Future Oncology</i> , 2019 , 15, 2423-2433	3.6	48
106	Avelumab in gastric cancer. <i>Immunotherapy</i> , 2019 , 11, 759-768	3.8	8
105	Novel Agents in Heavily Pretreated Metastatic Gastric Cancer: More Shadows Than Lights. <i>Journal of Oncology</i> , 2019 , 2019, 5692317	4.5	5
104	The relationship between KLK3 rs17632542 and PRNCR1 rs16901979 polymorphisms with susceptibility to prostate cancer. <i>Meta Gene</i> , 2019 , 21, 100595	0.7	

103	GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up. <i>Frontiers in Oncology</i> , 2019 , 9, 1102	5.3	11
102	Poor outcome for patients with gastric cancer and lung metastases treated with ramucirumab and paclitaxel. <i>Anti-Cancer Drugs</i> , 2019 , 30, e0789	2.4	2
101	Influence of Age and the Gleason Score in the Choice of Novel Hormonal Therapies Before and After Chemotherapy. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2019 , 34, 141-146	3.9	2
100	KRAS Mutation in Gastric Cancer and Prognostication Associated with Microsatellite Instability Status. <i>Pathology and Oncology Research</i> , 2019 , 25, 333-340	2.6	21
99	Pain predicts overall survival in men with metastatic castration-resistant prostate cancer treated with radium-223. <i>OncoTargets and Therapy</i> , 2019 , 12, 9-13	4.4	6
98	Is the fatigue an adverse event of the second generation of hormonal therapy? Data from a literature-based meta-analysis. <i>Medical Oncology</i> , 2018 , 35, 29	3.7	7
97	The prognostic value of PI3K mutational status in breast cancer: A meta-analysis. <i>Journal of Cellular Biochemistry</i> , 2018 , 119, 4287-4292	4.7	43
96	Third-line treatment and Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018 , 45, 496-508	8.8	117
95	The Role of Microsatellite Instability in Positive Margin Gastric Cancer Patients. <i>Surgical Innovation</i> , 2018 , 25, 99-104	2	9
94	Lenvatinib for the treatment of renal cell carcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2018 , 27, 507-512	5.9	6
93	Are EGFR tyrosine kinase inhibitors effective in elderly patients with EGFR-mutated non-small cell lung cancer?. <i>Clinical and Experimental Medicine</i> , 2018 , 18, 15-20	4.9	30
92	Meta-analysis of microsatellite instability in relation to clinicopathological characteristics and overall survival in gastric cancer. <i>British Journal of Surgery</i> , 2018 , 105, 159-167	5.3	123
91	Re: Silke Gillessen, Gerhardt Attard, Tomasz M. Beer, et al. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. <i>Eur Urol</i> 2018;73:178-211. <i>European Urology</i> , 2018 , 73, e31	10.2	11
90	Current status of androgen receptor-splice variant 7 inhibitor niclosamide in castrate-resistant prostate-cancer. <i>Investigational New Drugs</i> , 2018 , 36, 1133-1137	4.3	14
89	Familial aggregation of gastric cancer with microsatellite instability. <i>Acta Chirurgica Belgica</i> , 2018 , 118, 287-293	0.9	2
88	Meet Our Associate Editorial Board Member. <i>Current Clinical Pharmacology</i> , 2018 , 12, 201-201	2.5	
87	Acute Massive and Submassive Pulmonary Embolism: Preliminary Validation of Aspiration Mechanical Thrombectomy in Patients with Contraindications to Thrombolysis. <i>CardioVascular and Interventional Radiology</i> , 2018 , 41, 1840-1848	2.7	11
86	Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer. <i>Cells</i> , 2018 , 7,	7.9	32

85	Lower urinary tract infections from external beam radiation therapy in prostate cancer: A single institution experience. <i>Reports of Practical Oncology and Radiotherapy</i> , 2018 , 23, 298-299	1.5	
84	Association between ramucirumab-related hypertension and response to treatment in patients with metastatic gastric cancer. <i>Oncotarget</i> , 2018 , 9, 22332-22339	3.3	11
83	Meet Our Associate Editorial Board Member. <i>Current Pharmaceutical Biotechnology</i> , 2018 , 19, 683-683	2.6	
82	Corticosteroid switch in heavily pre-treated castration-resistant prostate cancer patients progressed on abiraterone acetate plus prednisone. <i>Investigational New Drugs</i> , 2018 , 36, 1110-1115	4.3	7
81	Pertuzumab therapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer. <i>Lancet Oncology, The</i> , 2018 , 19, 1270-1272	21.7	4
80	Docetaxel, oxaliplatin, 5FU, and trastuzumab as first-line therapy in patients with human epidermal receptor 2-positive advanced gastric or gastroesophageal junction cancer: Preliminary results of a phase II study. <i>Medicine (United States)</i> , 2018 , 97, e10745	1.8	8
79	The Italian Research Group for Gastric Cancer (GIRCG) guidelines for gastric cancer staging and treatment: 2015. <i>Gastric Cancer</i> , 2017 , 20, 20-30	7.6	110
78	Is still there a place for orteronel in management of prostate cancer? Data from a literature based meta-analysis of randomized trials. <i>Critical Reviews in Oncology/Hematology</i> , 2017 , 113, 18-21	7	3
77	The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials. <i>European Journal of Cancer</i> , 2017 , 75, 245-258	7.5	66
76	Targeting VEGFR-2 in Metastatic Gastric Cancer: Results From a Literature-Based Meta-Analysis. <i>Cancer Investigation</i> , 2017 , 35, 187-194	2.1	9
75	Advances in systemic therapy for metastatic breast cancer: future perspectives. <i>Medical Oncology</i> , 2017 , 34, 119	3.7	26
74	Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility. <i>Tumor Biology</i> , 2017 , 39, 1010428317695023	2.9	41
73	Single Center Experience on Anatomy-and Histopathology-Based Gastric Cancer Molecular Classification. <i>Cancer Investigation</i> , 2017 , 35, 325-332	2.1	4
72	Risk of hypertension with ramucirumab-based therapy in solid tumors: data from a literature based meta-analysis. <i>Investigational New Drugs</i> , 2017 , 35, 518-523	4.3	9
71	Is still there a role for IL-2 for solid tumors other than melanoma or renal cancer?. <i>Immunotherapy</i> , 2017 , 9, 25-32	3.8	6
70	Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: A meta-regression of randomised prospective studies. <i>European Journal of Cancer</i> , 2017 , 86, 257-265	7.5	21
69	Circulating tumor cells correlate with patterns of recurrence in patients with hormone-sensitive prostate cancer. <i>OncoTargets and Therapy</i> , 2017 , 10, 3811-3815	4.4	4
68	Enteric-coated and highly standardized cranberry extract reduces antibiotic and nonsteroidal anti-inflammatory drug use for urinary tract infections during radiotherapy for prostate carcinoma. <i>Research and Reports in Urology</i> , 2017 , 9, 65-69	1.3	4

67	Low dose versus standard dose of corticosteroids in the management of adverse events of special interest from abiraterone acetate: data from a literature-based meta-analysis. <i>Medical Oncology</i> , 2017 , 34, 166	3.7	2
66	Influence of Prior Tyrosine Kinase Inhibitor on Survival for Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab or Cabozantinib: Data from a Literature-based Meta-analysis. <i>European Urology</i> , 2017 , 72, 1027-1028	10.2	0
65	Could gonadotropin-releasing hormone analogs be helpful in the treatment of triple-negative breast cancer?. <i>Future Oncology</i> , 2017 , 13, 2473-2477	3.6	2
64	PAK6-Associated Support Vector Machine Classifier: A New Way to Evaluate Response and Survival of Gastric Cancer Treated by 5-FU/Oxaliplatin Chemotherapy. <i>EBioMedicine</i> , 2017 , 22, 18-19	8.8	3
63	Molecular key to understand the gastric cancer biology in elderly patients-The role of microsatellite instability. <i>Journal of Surgical Oncology</i> , 2017 , 115, 344-350	2.8	15
62	Low-Dose Oral Ethinylestradiol With Concomitant Low-Dose Acetylsalicylic Acid for Advanced Castrate-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, 371-375	3.3	0
61	Re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. <i>Eur Urol</i> . In press. http://dx.doi.org/10.1016/j.eururo.2016.06.033 . <i>European Urology</i> , 2017 , 71, e55	10.2	
60	Isolated Testicular Metastasis from Prostate Cancer. <i>American Journal of Case Reports</i> , 2017 , 18, 887-889	1.3	7
59	Hypoxia-related biological markers as predictors of epirubicin-based treatment responsiveness and resistance in locally advanced breast cancer. <i>Oncotarget</i> , 2017 , 8, 78870-78881	3.3	4
58	Need for randomized clinical trials testing targeted therapies in malignant pleural mesothelioma. <i>Lung Cancer</i> , 2017 , 114, 103-105	5.9	1
57	Is the Gleason score the driver for the treatment decision-making of patients with castration-resistant prostate cancer in the new era of the anti-androgenic therapies?. <i>Annals of Oncology</i> , 2016 , 27, 2131-2133	10.3	1
56	Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with T2 to T4, N0 and N1 breast cancer. <i>Breast</i> , 2016 , 29, 55-61	3.6	3
55	Role of targeted agents in neuroendocrine tumors: Results from a meta-analysis. <i>Cancer Biology and Therapy</i> , 2016 , 17, 883-8	4.6	5
54	Apatinib in metastatic gastric cancer: can paclitaxel make the difference?. <i>Anti-Cancer Drugs</i> , 2016 , 27, 809	2.4	3
53	Re: Karim Fizazi, Kim N. Chi, Johann S. de Bono, et al. Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer. <i>Eur Urol</i> . In press. http://dx.doi.org/10.1016/j.eururo.2016.02.035 : Corticosteroid-associated Adverse Events in A Phase II study of olaparib in breast cancer patients: biological evaluation from a window of opportunity trial. <i>Future Oncology</i> , 2016 , 12, 2189-93	10.2	2
52		3.6	7
51	Neoadjuvant chemotherapy and radical radiotherapy associated with cetuximab for laryngeal cancer in a pancreas and renal recipient. <i>Anti-Cancer Drugs</i> , 2016 , 27, 470-3	2.4	3
50	Clinical value and impact on prognosis of peri-operative CA 19-9 serum levels in stage I and II adenocarcinoma of the pancreas. <i>Tumor Biology</i> , 2016 , 37, 1959-66	2.9	14

49	Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer. <i>Cancer Letters</i> , 2016 , 372, 187-91	9.9	100
48	Strong Prognostic Value of Microsatellite Instability in Intestinal Type Non-cardia Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2016 , 23, 943-50	3.1	70
47	Monoclonal antibodies-based treatment in gastric cancer: current status and future perspectives. <i>Tumor Biology</i> , 2016 , 37, 127-40	2.9	8
46	Angiogenesis inhibitors in gastric and gastroesophageal junction cancer. <i>Gastric Cancer</i> , 2016 , 19, 31-41	7.6	42
45	Surgical management of advanced gastric cancer: An evolving issue. <i>European Journal of Surgical Oncology</i> , 2016 , 42, 18-27	3.6	54
44	Incidence and relative risk of adverse events of special interest in patients with castration resistant prostate cancer treated with CYP-17 inhibitors: A meta-analysis of published trials. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 101, 12-20	7	30
43	Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for treatment of ovarian cancer. <i>International Journal of Hyperthermia</i> , 2016 , 32, 298-310	3.7	21
42	Evolution and emerging future of cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion in gastric cancer: From treating the incurable to preventing recurrence. <i>International Journal of Hyperthermia</i> , 2016 , 32, 173-9	3.7	7
41	Is there a Place for Bevacizumab in Patients with Extensive-Stage Small Cell Lung Cancer?. <i>Current Cancer Drug Targets</i> , 2016 , 16, 209-14	2.8	3
40	No Advantage in Survival With Targeted Therapies as Maintenance in Patients With Limited and Extensive-Stage Small Cell Lung Cancer: A Literature-Based Meta-Analysis of Randomized Trials. <i>Clinical Lung Cancer</i> , 2016 , 17, 334-340	4.9	10
39	Apatinib for the treatment of gastric cancer. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016 , 10, 887-92	4.2	38
38	New molecular therapies in patients with advanced Hepatocellular Cancer in second line of treatment: Is a real defeat?: Results from a literature based meta-analysis of randomized trials. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 108, 62-68	7	2
37	Targeting the androgenic pathway in elderly patients with castration-resistant prostate cancer: A meta-analysis of randomized trials. <i>Medicine (United States)</i> , 2016 , 95, e4636	1.8	4
36	High-risk and low-risk gastric cancer areas in Italy and its association with microsatellite instability. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016 , 142, 1817-24	4.9	3
35	A Phase Ib Open-Label Study to Assess the Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-Negative Breast Cancers. <i>Clinical Breast Cancer</i> , 2016 , 16, e57-9	3	4
34	Epirubicin-based compared with docetaxel-based chemotherapy for advanced gastric carcinoma: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 102, 82-8	7	26
33	Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trials. <i>European Journal of Cancer</i> , 2016 , 61, 111-21	7.5	41
32	Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study. <i>Cancer Chemotherapy and Pharmacology</i> , 2015 , 75, 683-90	3.5	17

31	Rechallenge of docetaxel combined with epirubicin given on a weekly schedule in advanced castration-resistant prostate cancer patients previously exposed to docetaxel and abiraterone acetate: a single-institution experience. <i>Medical Oncology</i> , 2015 , 32, 52	3.7	17
30	Cisplatin, Etoposide, and Bevacizumab Regimen Followed by Oral Etoposide and Bevacizumab Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer: A Single-Institution Experience. <i>Clinical Lung Cancer</i> , 2015 , 16, e229-34	4.9	11
29	c-Met targeting in advanced gastric cancer: An open challenge. <i>Cancer Letters</i> , 2015 , 365, 30-6	9.9	51
28	Role of chemotherapy in the treatment of metastatic castration-resistant prostate cancer patients who have progressed after abiraterone acetate. <i>Cancer Chemotherapy and Pharmacology</i> , 2015 , 76, 439-45	2.5	5
27	The third line of treatment for metastatic prostate cancer patients: Option or strategy?. <i>Critical Reviews in Oncology/Hematology</i> , 2015 , 95, 265-71	7	11
26	Hyperthermic intraperitoneal chemotherapy for the treatment of ovarian cancer: A brief overview of recent results. <i>Critical Reviews in Oncology/Hematology</i> , 2015 , 95, 297-305	7	10
25	Sequential treatment with epirubicin, oxaliplatin and 5FU (EOF) followed by docetaxel, oxaliplatin and 5FU (DOF) in patients with advanced gastric or gastroesophageal cancer: a single-institution experience. <i>Cancer Chemotherapy and Pharmacology</i> , 2015 , 75, 941-7	3.5	22
24	Switch maintenance treatment with oral vinorelbine and bevacizumab after induction chemotherapy with cisplatin, gemcitabine and bevacizumab in patients with advanced non-squamous non-small cell lung cancer: a phase II study. <i>Medical Oncology</i> , 2015 , 32, 134	3.7	12
23	Five years of stable disease with maintenance therapy using bevacizumab and tamoxifen in a patient with metastatic breast cancer. <i>Cancer Biology and Therapy</i> , 2015 , 16, 493-7	4.6	2
22	Treatment of advanced oesophagogastric cancer with FOLFOX-4 regimen followed by leucovorin/bolus and continuous infusion 5-FU as maintenance chemotherapy in patients aged ≥ 75 years with impaired performance status. <i>Journal of Geriatric Oncology</i> , 2015 , 6, 380-6	3.6	6
21	An exceptional overall survival using bevacizumab beyond progression in a patient with non-small cell lung cancer. <i>Cancer Biology and Therapy</i> , 2015 , 16, 1720-5	4.6	1
20	Low-Dose Estramustine Phosphate and Concomitant Low-Dose Acetylsalicylic Acid in Heavily Pretreated Patients With Advanced Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, 441-6	3.3	7
19	Maintenance treatment with oral cyclophosphamide and bevacizumab in patients with recurrent epithelial ovarian cancer. <i>Future Oncology</i> , 2015 , 11, 2563-74	3.6	1
18	Tolerability of cabazitaxel in patients with metastatic castration-resistant prostate cancer progressing after docetaxel and abiraterone acetate: a single-institution experience. <i>Anti-Cancer Drugs</i> , 2015 , 26, 884-7	2.4	4
17	Abiraterone in heavily pretreated patients with metastatic castrate-resistant prostate cancer: final analysis of overall survival. <i>Anti-Cancer Drugs</i> , 2015 , 26, 910-1	2.4	3
16	Carboplatin, methotrexate, vinblastine, and epirubicin (M-VEC _a) as salvage treatment in patients with advanced bladder cancer: a phase II study. <i>Anti-Cancer Drugs</i> , 2015 , 26, 878-83	2.4	2
15	The distinctive nature of adenocarcinoma of the lung. <i>OncoTargets and Therapy</i> , 2015 , 8, 2399-406	4.4	12
14	Targeted Therapies for Prostate Cancer. <i>Cancer Investigation</i> , 2015 , 33, 276-85	2.1	5

13	Is there still a place for docetaxel rechallenge in prostate cancer?. <i>World Journal of Clinical Oncology</i> , 2015 , 6, 99-103	2.5	15
12	Three-weekly oxaliplatin combined with gemcitabine and capecitabine in the first-line treatment of patients with advanced biliary tract cancer. <i>Anti-Cancer Drugs</i> , 2015 , 26, 682-6	2.4	2
11	Reduced Dose of Abiraterone Acetate with Concomitant Low-dose Prednisone in the Treatment of 85 Year-old Patients with Advanced Castrate-resistant Prostate Cancer. <i>Anticancer Research</i> , 2015 , 35, 3097-102	2.3	3
10	How to optimize the sequential use of novel therapeutics in metastatic prostate cancer patients? Response should be found in prostate cancer tissue. <i>Tumor Biology</i> , 2014 , 35, 7391-2	2.9	3
9	Effects of abiraterone acetate on chronic kidney disease in 2 patients with metastatic castration-resistant prostate cancer. <i>Medicine (United States)</i> , 2014 , 93, e163	1.8	2
8	PSA response rate as a surrogate marker for median overall survival in docetaxel-based first-line treatments for patients with metastatic castration-resistant prostate cancer: an analysis of 22 trials. <i>Tumor Biology</i> , 2014 , 35, 10601-7	2.9	18
7	No clear evidence of a clinical benefit of a sequential therapy regimen with abiraterone acetate and enzalutamide. <i>Expert Review of Anticancer Therapy</i> , 2014 , 14, 1135-40	3.5	21
6	Abiraterone in heavily pretreated patients with metastatic castrate-resistant prostate cancer. <i>Anti-Cancer Drugs</i> , 2014 , 25, 472-7	2.4	7
5	Safety of sorafenib therapy in elderly adults with advanced hepatocellular carcinoma. <i>Journal of the American Geriatrics Society</i> , 2014 , 62, 2204-5	5.6	5
4	Time for a revision on the role of PSA response rate as a surrogate marker for median overall survival in docetaxel-based first-line treatment for patients with metastatic hormone-refractory prostate cancer. <i>International Journal of Biological Markers</i> , 2013 , 28, 326-8	2.8	3
3	A husband and a wife with simultaneous presentation of glioblastoma multiforme: a case report. <i>Case Reports in Oncology</i> , 2013 , 6, 538-43	1	3
2	CEA and CA19.9 as early predictors of progression in advanced/metastatic colorectal cancer patients receiving oxaliplatin-based chemotherapy and bevacizumab. <i>Cancer Investigation</i> , 2012 , 30, 65-71	2.1	31
1	Bevacizumab and weekly docetaxel in patients with metastatic castrate-resistant prostate cancer previously exposed to docetaxel. <i>Prostate Cancer</i> , 2011 , 2011, 258689	1.9	14